Ibrutinib PK data ( @,@ observations/@ patients ) were available from the following clinical studies : ( @ ) A phase I dose-escalation study in recurrent B cell malignancies ( dose levels of @-@ @ mg/kg/day and fixed dose of @ mg/day ) ; ( @ ) a phase II study in MCL ( fixed dose level of @ mg/day ) ; ( @ ) a phase Ib/II dose-finding study in CLL ( fixed dose levels of @ and @ mg/day ) .